Red Cross Suspends HemaSure r\LS Leukoreduction On Adverse Event Reports
This article was originally published in The Gray Sheet
Executive Summary
HemaSure and American Red Cross reps will meet, together with outside medical advisors, the week of April 17 to assess data gathered in the investigation of adverse events that have prompted ARC to suspend use of the firm's r\LS leukocyte reduction filter.